Linda Yaccarino’s next role after departing X as CEO will be another chief executive position at eMed Population Health, an AI startup developing a technology platform for patients using GLP-1 drugs. Yaccarino, a longtime advertising executive at NBCUniversal, left to join X as CEO for two years. During her tenure, she made a positive impact on the social network’s struggling ad revenue model, despite her and Elon Musk’s shared approach of minimizing content moderation.
Though Yaccarino lacks experience in health tech, eMed stated in a press release that they pursued her for her “undeniable ability to negotiate new partnerships.” Her high-profile role at X also raised her visibility in the tech world, bringing additional attention to the startup.
Previously, eMed developed a tech platform designed for at-home COVID-19 rapid antigen tests, guiding users through the proper administration process. Now, the company is shifting its focus to GLP-1 drugs, such as Ozempic, which are used for weight management and treating type 2 diabetes.
Yaccarino commented in a press release, “To be a leader in today’s healthcare marketplace, companies need to have a fearless tenacity that allows them not only to grow but also to step forward and redefine an entire industry. We are very well-positioned to be that tenacious leader, striving toward our ultimate goal of improving global healthcare outcomes through our groundbreaking services and platforms.”